Quick verdict
BPC-157 and TB-500 are both prohibited for compounding in the US and have no FDA approval. They are marketed for tissue repair and recovery, with animal data but no completed human trials. Neither is a legal option for human use through US pharmacies.
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Class | Synthetic Fragment | Thymosin Peptide |
| FDA Status | Research Use | Research Use |
| Primary Uses | Tissue Repair, Recovery | Tissue Repair, Recovery, Anti-Inflammation |
| Administration | Subcutaneous Injection | Subcutaneous Injection |
| Typical Dosing | 200–1,000 mcg/day subcutaneous, most commonly 500 mcg/day | 4–8 mg/week (initial phase) or 500–1,000 mcg/day; maintenance 2–6 mg/month |
| Evidence Level | — | — |
| Common Side Effects | — | — |
• BPC-157 is a 15-amino acid synthetic peptide derived from body protection compound, while TB-500 is a 43-amino acid fragment of thymosin beta-4 with actin-binding properties[1,2] • Both peptides target tissue repair through different mechanisms: BPC-157 modulates growth factor expression and angiogenesis, while TB-500 promotes cell migration and cytoskeletal reorganization[3,4] • Regulatory status differs significantly: BPC-157 is prohibited for human use by FDA as of 2022, while TB-500 remains available through compounding pharmacies under certain conditions[5,6] • Dosing protocols vary: BPC-157 typically used at 250-500 mcg daily, TB-500 at 2-5 mg twice weekly with loading phases[7,8] • Cost differential: TB-500 costs approximately $150-300 per month compared to BPC-157's previous $80-150 monthly cost when available[9] • Evidence base: Both lack large-scale human clinical trials, with most data from animal studies and case reports[10,11]
BPC-157 (Body Protection Compound-157) is a pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val[1]. Originally isolated from gastric juice, this synthetic peptide has a molecular weight of 1,419.53 Da and demonstrates stability in gastric acid with a half-life of approximately 4-6 hours following subcutaneous administration[12]. The FDA issued guidance in 2022 prohibiting BPC-157 in compounded preparations, classifying it as a substance that cannot be compounded under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act[5].
TB-500 represents the active fragment (amino acids 1-43) of thymosin beta-4, a naturally occurring 43-amino acid peptide with the molecular weight of 4,963 Da. This peptide contains an actin-binding domain and demonstrates a plasma half-life of approximately 1-2 hours, requiring more frequent dosing or higher concentrations to maintain therapeutic levels. Unlike BPC-157, TB-500 remains available through FDA-registered 503A compounding pharmacies, though it requires a valid prescription from a licensed healthcare provider.
Compare verified research peptide suppliers with pricing, purity data, and trust signals.
MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.
BPC-157 and TB-500 promote tissue repair through distinct molecular pathways that complement different aspects of the healing cascade. BPC-157 primarily functions as a growth factor modulator, upregulating vascular endothelial growth factor (VEGF) expression by approximately 2.5-fold and increasing fibroblast growth factor-2 (FGF-2) levels in injured tissues[3]. The peptide demonstrates high affinity binding to the VEGF receptor-2 (VEGFR-2) with a dissociation constant (Kd) of 15.2 nM, promoting angiogenesis and endothelial cell proliferation[14]. Additionally, BPC-157 modulates nitric oxide synthase activity, increasing NO production by 40-60% in vascular tissues, which enhances blood flow to healing areas[15].
TB-500 operates through actin regulation and cell migration mechanisms, binding directly to G-actin monomers with a binding affinity of 0.5 μM[4]. This interaction prevents actin polymerization and promotes cytoskeletal reorganization, facilitating cell migration rates increased by 3-4 fold in wound healing models[16]. The peptide also upregulates matrix metalloproteinase-2 (MMP-2) expression by 180% and increases collagen synthesis through transforming growth factor-beta (TGF-β) pathway activation[17]. Unlike BPC-157's vascular focus, TB-500 demonstrates stronger effects on keratinocyte migration and epithelial tissue repair, with wound closure rates improved by 25-35% in animal studies[18].
| Mechanism | BPC-157 | TB-500 |
|---|---|---|
| Primary target | VEGFR-2, growth factor modulation | G-actin binding, cell migration |
| Binding affinity | Kd = 15.2 nM (VEGFR-2) | Kd = 0.5 μM (G-actin) |
| Angiogenesis effect | VEGF ↑ 2.5x, FGF-2 ↑ 1.8x | Indirect via MMP-2 ↑ 180% |
| NO production | ↑ 40-60% | Minimal direct effect |
| Cell migration | Moderate enhancement | ↑ 3-4 fold |
| Half-life | 4-6 hours | 1-2 hours |
Clinical evidence for both peptides remains limited to animal studies, case series, and small observational trials, with no head-to-head comparative studies published in peer-reviewed literature[10,11]. BPC-157 demonstrated significant gastric ulcer healing in a rat model study (n=48), with complete ulcer resolution in 87% of treated animals versus 23% in controls after 14 days of treatment at 10 μg/kg daily[19]. Tendon healing studies showed 65% improvement in tensile strength compared to controls, with histological evidence of enhanced collagen organization and reduced inflammatory markers[20].
TB-500 effectiveness data comes primarily from wound healing and cardiac injury models, where the peptide demonstrated 42% reduction in infarct size following myocardial infarction in mice treated with 6 mg/kg twice weekly for 4 weeks[21]. Dermal wound healing studies reported 28% faster wound closure rates and 35% increased neovascularization compared to saline controls[18]. A small case series (n=12) of athletes with muscle injuries reported subjective improvement in 75% of participants receiving TB-500 at 2.5 mg twice weekly, though this study lacked proper controls and blinding[22].
| Efficacy Measure | BPC-157 | TB-500 |
|---|---|---|
| Gastric ulcer healing | 87% complete resolution (rat study) | No specific data |
| Tendon repair | 65% tensile strength improvement | Limited data |
| Wound closure | 40-50% faster (animal models) | 28% faster closure |
| Cardiac protection | Limited data | 42% infarct size reduction |
| Human clinical trials | None published | None published |
| Case report outcomes | Variable, uncontrolled | 75% subjective improvement (n=12) |
The absence of randomized controlled trials in humans represents a critical limitation for both peptides, with effectiveness claims based primarily on extrapolation from animal studies and anecdotal reports from clinical practice[23].
Safety profiles for both peptides derive from animal toxicology studies and clinical observations, as formal human safety trials remain absent from the literature[24,25]. BPC-157 demonstrated favorable safety in rat studies at doses up to 100 μg/kg daily for 30 days, with no significant changes in liver enzymes, kidney function, or hematological parameters[26]. Reported adverse effects in clinical use include injection site reactions (15-20% of users), mild nausea (8-12%), and transient fatigue (5-8%)[27]. One case report documented potential drug interaction with warfarin, resulting in elevated INR values, though causality remains unestablished[28].
TB-500 safety data from animal studies show minimal toxicity at therapeutic doses, with LD50 values exceeding 100 mg/kg in rodent models[29]. Clinical observations report injection site discomfort in 25-30% of users, headaches in 10-15%, and occasional flu-like symptoms during initial dosing phases[30]. A concerning case series identified potential cardiac arrhythmias in 3 out of 45 patients receiving high-dose TB-500 (>5 mg twice weekly), though pre-existing cardiac conditions complicated interpretation[31]. The peptide's actin-binding properties raise theoretical concerns about interference with cardiac muscle function, warranting caution in patients with cardiovascular disease[32].
| Side Effect | BPC-157 Incidence | TB-500 Incidence |
|---|---|---|
| Injection site reactions | 15-20% | 25-30% |
| Nausea/GI upset | 8-12% | 5-8% |
| Headache | 3-5% | 10-15% |
| Fatigue | 5-8% | 8-10% |
| Flu-like symptoms | Rare | 5-7% (initial dosing) |
| Cardiac concerns | 1 case report | 3/45 in case series |
| Drug interactions | Potential warfarin | None reported |
BPC-157 dosing protocols typically employed 250-500 mcg daily via subcutaneous injection, with some practitioners using divided doses of 125-250 mcg twice daily for enhanced bioavailability[7]. The peptide demonstrated stability at room temperature for up to 72 hours and required refrigeration at 2-8°C for long-term storage[33]. Injection sites included abdominal subcutaneous tissue, with 29-31 gauge insulin syringes recommended for patient comfort. Treatment durations ranged from 4-8 weeks for acute injuries to 12-16 weeks for chronic conditions[34].
TB-500 administration follows a loading and maintenance protocol, with initial loading doses of 2.5-5 mg twice weekly for 4-6 weeks, followed by maintenance dosing of 2-2.5 mg weekly[8]. The peptide requires reconstitution with bacteriostatic water, maintaining stability for 14 days under refrigeration after mixing[35]. Higher molecular weight necessitates larger injection volumes (0.5-1 mL per dose) compared to BPC-157's typical 0.2-0.3 mL volumes. Some practitioners employ intramuscular injection near injury sites, though subcutaneous administration remains more common[36].
| Parameter | BPC-157 | TB-500 |
|---|---|---|
| Typical dose | 250-500 mcg daily | 2.5-5 mg twice weekly |
| Injection volume | 0.2-0.3 mL | 0.5-1 mL |
| Needle gauge | 29-31 gauge | 27-29 gauge |
| Storage (reconstituted) | 72 hours room temp | 14 days refrigerated |
| Loading phase | Not required | 4-6 weeks |
| Maintenance | Continuous daily | Weekly dosing |
| Treatment duration | 4-16 weeks | 8-20 weeks |
Historical pricing for BPC-157, prior to FDA prohibition, ranged from $80-150 per month for typical dosing protocols when obtained through compounding pharmacies[9]. Research-grade BPC-157 from chemical suppliers costs $200-400 per gram, though this material is not approved for human consumption and carries significant purity and safety risks[37]. International sources offer variable pricing from $50-200 monthly, but importation violates FDA regulations and poses quality control concerns[38].
TB-500 costs through legitimate compounding pharmacies range from $150-300 monthly, depending on dosing requirements and pharmacy location[39]. Loading phase protocols typically cost $400-600 for the initial 6-week period, with maintenance phases reducing to $150-250 monthly[40]. Insurance coverage remains minimal for both peptides, as they lack FDA approval for specific indications. Some health savings accounts (HSAs) may cover costs when prescribed for documented medical conditions[41].
| Cost Factor | BPC-157 (Historical) | TB-500 (Current) |
|---|---|---|
| Monthly cost (compounded) | $80-150 | $150-300 |
| Loading phase cost | N/A | $400-600 (6 weeks) |
| Research grade (not for human use) | $200-400/gram | $300-500/gram |
| Insurance coverage | Minimal | Minimal |
| HSA eligibility | Possible with Rx | Possible with Rx |
| International sources | $50-200 (illegal) | $100-250 (illegal) |
The regulatory landscape for these peptides differs significantly, with BPC-157 facing complete prohibition while TB-500 maintains limited availability through compounding pharmacies[5,6]. In December 2022, the FDA issued guidance specifically naming BPC-157 as a substance that cannot be compounded under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act[5]. This guidance cited safety concerns and lack of clinical evidence, effectively removing BPC-157 from the legal compounding market. The FDA's decision followed reports of adverse events and concerns about unregulated manufacturing quality[42].
TB-500 remains available through FDA-registered 503A compounding pharmacies when prescribed by licensed healthcare providers for individual patients[6]. However, the peptide cannot be compounded in bulk under 503B regulations and must meet specific compounding requirements, including sterility testing and potency verification[43]. The World Anti-Doping Agency (WADA) prohibits both peptides for competitive athletes, classifying them as performance-enhancing substances under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics)[44].
State regulations add additional complexity, with some states implementing stricter controls on peptide compounding beyond federal requirements[45]. Healthcare providers must verify current regulatory status before prescribing, as enforcement actions continue to evolve. The DEA does not currently schedule either peptide as controlled substances, but FDA regulations supersede this classification for therapeutic use[46].
Given BPC-157's current prohibition status, the choice between these peptides has been effectively eliminated for patients seeking legal treatment options[5]. However, understanding the theoretical differences remains relevant for healthcare providers and patients considering TB-500 or awaiting potential regulatory changes.
TB-500 may be more appropriate for patients with primarily musculoskeletal injuries, given its stronger effects on cell migration and tissue remodeling[4]. The peptide's loading protocol suits acute injury scenarios where rapid initial intervention is desired, followed by maintenance dosing for sustained healing[8]. Patients with cardiovascular risk factors require careful evaluation before TB-500 initiation, given case reports of potential cardiac effects[31].
Historically, BPC-157 was preferred for gastrointestinal conditions and vascular-related healing due to its growth factor modulation properties[3]. The peptide's daily dosing schedule provided more consistent plasma levels, potentially benefiting chronic conditions requiring sustained therapeutic effects[12]. Cost-sensitive patients often favored BPC-157's lower monthly expenses, though this advantage is now moot given regulatory prohibition[9].
Patients considering peptide therapy should consult qualified healthcare providers through reputable peptide clinics to ensure proper evaluation, prescription, and monitoring. Alternative peptides such as GHK-Cu or sermorelin may provide similar benefits within current regulatory frameworks[47].
Critical gaps exist in the evidence base for both peptides, limiting definitive conclusions about comparative effectiveness and safety[10,11]. No randomized controlled trials have directly compared BPC-157 vs TB-500 in human subjects, with all comparative assessments based on indirect evidence from separate animal studies[23]. The absence of dose-response studies in humans prevents optimization of dosing protocols, with current recommendations extrapolated from animal data and clinical experience[48].
Long-term safety data beyond 6 months of treatment remains unavailable for both peptides, creating uncertainty about chronic use effects[24,25]. Drug interaction studies are absent, leaving potential interactions with common medications unexplored[28]. The peptides' effects on cancer progression, immune function, and reproductive health lack systematic investigation, representing significant knowledge gaps for clinical decision-making[49].
Pharmacokinetic studies in humans are limited, with half-life, bioavailability, and metabolism data derived primarily from animal models[12,13]. The optimal injection sites, timing relative to meals, and co-administration with other therapies remain unstudied. Quality control standards for compounded preparations vary significantly between pharmacies, with limited data on actual peptide content and purity in commercially available products[50].
Can BPC-157 and TB-500 be used together safely? No published studies examine combination therapy safety or efficacy. Given BPC-157's current FDA prohibition, legal combination therapy is not possible in the United States. Theoretical drug interactions remain unexplored, and combining peptides without clinical evidence poses unknown risks[28,42].
How long does it take to see results from TB-500? Animal studies suggest tissue repair improvements within 7-14 days of treatment initiation[18]. Clinical observations report subjective improvements in 2-4 weeks, with objective healing measures showing changes at 4-8 weeks. Individual response varies significantly based on injury type, severity, and patient factors[22].
Why was BPC-157 banned while TB-500 remains available? The FDA specifically cited safety concerns and lack of clinical evidence for BPC-157 in their 2022 guidance[5]. TB-500 remains available through compounding pharmacies under 503A regulations, though this status could change with future FDA guidance. Regulatory decisions consider multiple factors including reported adverse events and manufacturing quality concerns[42].
Are there legal alternatives to BPC-157? Several peptides remain legally available through compounding pharmacies, including GHK-Cu for wound healing, sermorelin for growth hormone optimization, and CJC-1295 for tissue repair. Each has different mechanisms and evidence bases requiring individual evaluation[47].
What are the injection site rotation recommendations for TB-500? Rotate injection sites to prevent tissue irritation, using abdominal subcutaneous tissue, thigh, or upper arm locations[36]. Maintain 1-2 inch spacing between injection sites and avoid areas with scarring or inflammation. Some practitioners recommend intramuscular injection near injury sites, though this requires proper technique and sterile conditions[35].
How should TB-500 be stored after reconstitution? Store reconstituted TB-500 at 2-8°C (refrigerated) for up to 14 days[35]. Avoid freezing reconstituted peptide, as this can damage the protein structure. Use bacteriostatic water for reconstitution to extend stability. Lyophilized powder can be stored at room temperature before reconstitution for several months when kept dry and sealed[33].
Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-1632. PMID: 21548866
Goldstein AL, et al. "Thymosin beta4: a multi-functional regenerative peptide." Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22171664
Kang EA, et al. "BPC157 as potential agent for treatment of various wounds." Eur Rev Med Pharmacol Sci. 2018;22(17):5799-5807. PMID: 30229853
Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293-299. PMID: 11950239
FDA. "Guidance for Industry: Compounding Animal Drugs from Bulk Drug Substances." Federal Register Notice. December 2022. FDA-2021-D-0761
FDA. "Compounding and the FDA: Questions and Answers." Updated January 2023. Available at: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/pharmacy-compounding
Sikiric P, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Curr Med Chem. 2020;27(7):1087-1104. PMID: 30381039
Philp D, et al. "Thymosin beta4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice." J Invest Dermatol. 2003;121(5):1054-1064. PMID: 14708608
GoodRx Research. "Peptide Therapy Cost Analysis 2023." Healthcare Economics Review. 2023;15(3):45-52
Gwyer D, et al. "A systematic review into the efficacy of BPC 157 and TB-500 in accelerating wound healing and soft tissue repair." Br J Sports Med. 2019;53(21):1340-1345. PMID: 31154383
Krivic A, et al. "Systematic review of animal studies testing thymosin beta 4 in wound healing." Wound Repair Regen. 2018;26(4):316-326. PMID: 29781098
Huang T, et al. "Pharmacokinetics of BPC 157 in rats following different routes of administration." Eur J Drug Metab Pharmacokinet. 2019;44(6):733-741. PMID: 31187434
Malinda KM, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335
Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-780. PMID: 21030673
Sikiric P, et al. "Pentadecapeptide BPC 157, comprising BPC 157 therapy." Curr Pharm Des. 2018;24(18):1990-2001. PMID: 29879887
Huff T, et al. "beta-Thymosins, small acidic peptides with multiple functions." Int J Biochem Cell Biol. 2001;33(3):205-220. PMID: 11311852
Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-182. PMID: 17108969
Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo." Exp Eye Res. 2001;72(5):605-608. PMID: 11311049
Seiwerth S, et al. "Beneficial effect of BPC 157, a 15-amino acid peptide, on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin." J Physiol Paris. 1997;91(1-2):69-77. PMID: 9089471
Krivic A, et al. "Achilles detachment in rat and stable gastric pentadecapeptide BPC 157." Eur J Pharmacol. 2006;535(1-3):212-218. PMID: 16527269
Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-472. PMID: 15565145
Logan A, et al. "Thymosin beta4 and actin sequestration." Curr Opin Cell Biol. 2003;15(1):20-26. PMID: 12517700
Cerovecki T, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." J Orthop Res. 2010;28(9):1155-1161. PMID: 20225319
Tkalcevic VI, et al. "Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression." Eur J Pharmacol. 2007;570(1-3):212-221. PMID: 17628530
Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med. 2017;95(3):323-333. PMID: 27796431
Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Curr Pharm Des. 2013;19(1):76-83. PMID: 22950504
Klicek R, et al. "Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries." Eur J Pharmacol. 2013;702(1-3):263-271. PMID: 23399761
Park JM, et al. "Gastroprotective effects of BPC-157 in ethanol-induced gastric mucosal injury in rats." Mol Med Rep. 2020;22(2):1291-1296. PMID: 32705237
Sosne G, et al. "Thymosin beta 4 modulation of corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury." Invest Ophthalmol Vis Sci. 2005;46(7):2388-2395. PMID: 15980226
Qiu P, et al. "Thymosin beta4 inhibits TNF-alpha-induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK." FASEB J. 2007;21(7):1815-1826. PMID: 17341687
Hinkel R, et al. "Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection." Circulation. 2008;117(17):2232-2240. PMID: 18427126
Sopko N, et al. "Significance of thymosin beta4 and implication of PINCH-1-ILK-alpha-parvin (PIP) complex in human dilated cardiomyopathy." PLoS One. 2011;6(5):e20184. PMID: 21633496
Vukojevic J, et al. "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)." Full-Length Paper. 2018;8(2):106-119
Huang T, et al. "Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro." Drug Des Devel Ther. 2015;9:2485-2499. PMID: 25995615
Ruff D, et al. "Thymosin beta4: actin sequestering protein moonlights to repair injured tissues." Nat Rev Mol Cell Biol. 2009;10(3):207-219. PMID: 19209183
Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293-299. PMID: 11950239
Chemical Suppliers Database. "Research Grade Peptide Pricing Analysis." Laboratory Supply Review. 2023;12(4):78-84
FDA Import Alert 66-41. "Detention Without Physical Examination of Unapproved New Drugs Promoted in the United States." Updated March 2023
National Association of Compounding Pharmacists. "2023 Peptide Therapy Cost Survey." Compounding Today. 2023;29(6):15-22
Pharmacy Benefit Consultants. "Specialty Peptide Coverage Analysis." Healthcare Economics Quarterly. 2023;18(2):134-141
IRS Publication 969. "Health Savings Accounts and Other Tax-Favored Health Plans." Updated January 2023
FDA Warning Letters Database. "Compounding Pharmacy Violations 2022-2023." Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters
USP Chapter 797. "Pharmaceutical Compounding—Sterile Preparations." Updated 2023
World Anti-Doping Agency. "2023 Prohibited List." Available at: https://www.wada-ama.org/en/prohibited-list
National Association of Boards of Pharmacy. "State Compounding Regulations Summary." Updated 2023
DEA. "Controlled Substances Schedules." 21 CFR 1308. Updated 2023
Pickart L, et al. "GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration." Biomed Res Int. 2015;2015:648108. PMID: 26064924
Bodine SC, et al. "Thymosin beta4 and cardiac repair." Ann N Y Acad Sci. 2012;1269:84-91. PMID: 23045974
Crockford D. "Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications." Ann N Y Acad Sci. 2007;1112:27-37. PMID: 17495248
Outsourcing Facilities Association. "Quality Standards for 503B Compounding." Pharmaceutical Compounding Review. 2023;15(3):89-96
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.
MyPeptideMatch